Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

November 11 th at 8:30 AM ET Hosted a Virtual Acute Myeloid Leukemia KOL event with internationally renowned Acute Myeloid ...

Highlights,Hemogenyx Pharmaceuticals secures funding for phase I trials of its HEMO-CAR-T therapy.,The therapy focuses on ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the ...

About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating today. Salim Syed’s rating ...

Fms-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML). FLT3 internal tandem duplication (ITD) plays an important role in shaping the clinical ...

HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update. Hemogenyx Pharmaceuticals has secured a £600,000 investment from an institutional ...

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Vor Biopharma (VOR – Research Report). The associated price ...

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at ...

Cellectis has deprioritized one of its leukemia-focused candidates in order to focus on its other two clinical-stage CAR-T therapies. | Cellectis has deprioritized one of its leukemia-focused ...